Scribe Therapeutics launches $129M IPO, kicking off second-half biotech listing spree
read at Endpoints ↗DealPositive
Scribe Therapeutics, a nine-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna, announced its initial public offering.
The company priced the IPO at about $128.7 million, raising roughly $129 million in the listing.
The offering is described as the kickoff for a series of biotech IPOs slated for the second half of the year.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Gene editor Scribe starts second-half IPO spree with $129M listing”
read at Endpoints ↗87 words · retrieved Jul 24
comments(0)
5-min edit window · permanent after that